Pi3K P110Α Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
|name=Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
|gene=PIK3CA
|uniprot=P42336
|pdb=2Y3A
|mw=126.8 kDa
|localization=Cytosolic, membrane-associated
|family=PI3K family
}}
p110α is the catalytic subunit of Class IA PI3K (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), encoded by the PIK3CA gene. PI3K is a central signaling molecule in cell growth, survival, and neuronal function. p110α is one of three Class IA catalytic subunits (p110α, p110β, p110δ) and is widely expressed in all tissues, including the brain. It plays critical roles in signal transduction downstream of receptor tyrosine kinases, G-protein coupled receptors, and integrin signaling. Dysregulation of PI3K/Akt signaling is implicated in Alzheimer's disease, Parkinson's disease, and various cancers.
p110α is a 126.8 kDa protein with multiple functional domains:
| Function | Mechanism | Brain Region |
|---|---|---|
| Synaptic plasticity | CREB activation, AMPA receptor trafficking | Hippocampus, Cortex |
| Neuronal survival | Akt-mediated BAD inactivation | Cortex, Hippocampus |
| Growth cone guidance | cytoskeletal reorganization | Developing neurons |
| Metabolism | Glucose uptake regulation | All brain regions |
| Autophagy | mTORC1 inhibition | All brain regions |
PI3K/Akt signaling is significantly impaired in Alzheimer's disease, contributing to multiple pathological features:
Therapeutic approaches targeting PI3K/Akt in AD include:
PI3K/Akt signaling provides neuroprotection in dopaminergic neurons:
Neuroprotective strategies:
| Approach | Agent | Mechanism | Development Stage |
|---|---|---|---|
| PI3K p110α inhibitors | Various | Reduce hyperactive PI3K | Research |
| Akt activators | SC79, A-443654 | Bypass PI3K | Preclinical |
| mTOR inhibitors | Rapamycin, Everolimus | Downstream modulation | Clinical trials |
| BDNF mimetics | peptide fragments | Activate PI3K pathway | Experimental |
| Growth factors | BDNF, GDNF | Activate PI3K/Akt | Clinical trials |
| Biomarker | Sample | Changes in Disease |
|---|---|---|
| p-Akt (Ser473) | Brain tissue | ↓ in AD/PD |
| p-PI3K | Brain tissue | ↓ in AD |
| PIP3 levels | Brain tissue | ↓ in AD |
| p-mTOR (Ser2448) | Brain tissue | ↑ in AD (feedback) |
The study of Pi3K P110Α Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657. PMID:12040186
[2] Zhou J, et al. The PI3K/Akt signaling pathway in Alzheimer's disease. J Alzheimer's Dis. 2022;86(1):31-44. PMID:35142679
[3] Han X, et al. PI3K/Akt signaling in Parkinson's disease. Mov Disord. 2021;36(8):1765-1778. PMID:34041752
[4] Burke JE. Structural basis for regulation of phosphoinositide 3-kinase. Annu Rev Biochem. 2023;92:115-147. PMID:37133928
[5] Liu Y, et al. Targeting PI3K/Akt signaling for neurodegeneration. Pharmacol Rev. 2024;76(2):245-278. PMID:38215284